Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Company Overview

Arcturus Therapeutics is a clinical-stage messenger RNA (mRNA) medicines company founded in 2013 and headquartered in San Diego, California. The firm is dedicated to the discovery, development and commercialization of therapeutics and vaccines based on its proprietary RNA platform. Arcturus leverages cutting-edge synthetic biology, lipid nanoparticle delivery systems and self-amplifying RNA (saRNA) constructs to address a broad range of rare diseases, metabolic disorders and infectious diseases.

The company’s core technology is its LUNAR® lipid-enabled delivery system, designed to transport RNA payloads efficiently to target tissues beyond the liver. By combining synthetic self-amplifying RNA with optimized lipid nanoparticle formulations, Arcturus aims to achieve durable protein expression at low dose levels. This platform underpins the development of both therapeutic candidates—such as enzyme replacement treatments for rare metabolic conditions—and vaccine candidates against pathogens like SARS-CoV-2.

Arcturus’s pipeline includes ARCT-810, an mRNA replacement therapy for ornithine transcarbamylase (OTC) deficiency, and ARCT-021 (also known as STARR™), a self-amplifying COVID-19 vaccine candidate that has advanced through early-stage clinical trials. The company also collaborates with biopharmaceutical partners to license its platform for additional indications, extending its reach into oncology, cardiovascular disease and other therapeutic areas. Manufacturing and clinical operations span multiple locations, including development sites in the United States and a research hub in Singapore.

Under the leadership of Chief Executive Officer Joseph Payne and Chief Financial Officer Leslie Fishman, Arcturus has built a management team with deep expertise in RNA science, drug development and regulatory strategy. The board and senior management draw on decades of experience from leading biotech and pharmaceutical organizations, positioning the company to navigate the complexities of advancing mRNA therapies from the laboratory to the clinic.

Key Stats

• Today's Range: $13.44 to $13.94
• 50-Day Range: $10.84 to $14.41
• 52-Week Range: $8.04 to $25.88
• Volume: 172,653 shs
• Average Volume: 421,186 shs
• Market Capitalization: $369.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $54.00
• Consensus Rating: Buy

Arcturus Therapeutics Stock Analysis - MarketRank™

Arcturus Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 241st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcturus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.22) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcturus Therapeutics is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcturus Therapeutics is -5.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcturus Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.02% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcturus Therapeutics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcturus Therapeutics does not currently pay a dividend.

Dividend Growth

Arcturus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

20.02% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcturus Therapeutics has recently decreased by 9.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.80

News Sentiment

Arcturus Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

3 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.60% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARCT Stock Analysis - Frequently Asked Questions

How have ARCT shares performed this year?

Arcturus Therapeutics' stock was trading at $16.97 at the beginning of 2025. Since then, ARCT shares have decreased by 19.7% and is now trading at $13.6350.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its earnings results on Monday, May, 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $1.06. The biotechnology company earned $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 47.47% and a negative trailing twelve-month return on equity of 27.41%.
Read the conference call transcript.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARCT
• CIK: 1410997
• Web: www.arcturusrx.com
• Phone: (858) 900-2660
• Fax: N/A
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $54.00
• High Stock Price Target: $70.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +296.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.94 million
• Net Margins: -47.47%
• Pretax Margin: -47.72%
• Return on Equity: -27.41%
• Return on Assets: -19.01%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 5.64
• Quick Ratio: 5.64

Sales & Book Value

• Annual Sales: $152.31 million
• Price / Sales: 2.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.90 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 27,120,000
• Free Float: 22,619,000
• Market Cap: $369.78 million
• Optionable: Optionable
• Beta: 2.27